Your browser doesn't support javascript.
loading
Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy.
Hudkins, Kelly L; Wietecha, Tomasz A; Steegh, Floor; Alpers, Charles E.
Afiliação
  • Hudkins KL; Department of Pathology, University of Washington, Seattle, Washington.
  • Wietecha TA; Department of Pathology, University of Washington, Seattle, Washington.
  • Steegh F; Department of Pathology, University of Washington, Seattle, Washington.
  • Alpers CE; Department of Pathology, University of Washington, Seattle, Washington.
Am J Physiol Renal Physiol ; 318(5): F1295-F1305, 2020 05 01.
Article em En | MEDLINE | ID: mdl-32249614

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistema Renina-Angiotensina / Losartan / Bloqueadores do Receptor Tipo 1 de Angiotensina II / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Podócitos / Antagonistas do Receptor de Endotelina A / Atrasentana Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sistema Renina-Angiotensina / Losartan / Bloqueadores do Receptor Tipo 1 de Angiotensina II / Diabetes Mellitus Tipo 2 / Nefropatias Diabéticas / Podócitos / Antagonistas do Receptor de Endotelina A / Atrasentana Idioma: En Ano de publicação: 2020 Tipo de documento: Article